$OraSure Technologies (OSUR.US)$ OraQuick® HIV Self-Test Now Approved for Use in Adolescents Tuesday, 7th January at 7:05 am BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older. According to the most recent data available from t...
$OraSure Technologies (OSUR.US)$ OraSure Technologies Acquires Sherlock Biosciences Thursday, 19th December at 4:02 pm BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraS...
$OraSure Technologies (OSUR.US)$ OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test OraSure Technologies (NASDAQ: OSUR) has received a federal contract through the Rapid Response Partnership Vehicle (RRPV) to develop a Marburg Virus Disease (MVD) rapid antigen test. The initial contract is valued at $7.5 million over multiple years, with potential value up to $11 million. The funding from BARDA aims to achieve FDA 510(k) clearance for a single-use lateral f...
The consistent ROCE and increase in capital employed suggest that OraSure Technologies is not investing in high return investments. The underlying trends do not inspire confidence in the potential for the company to become a multi-bagger in the future.
The low P/S ratio is ascribed to investors predicting the strong revenue growth will falter. The foreseen revenue decline justifies the low ratio. Without significant changes, a sharp stock price increase seems improbable.
$OraSure Technologies (OSUR.US)$In at 12.65. They had a good earnings report and people quite literally "sold the news". for you newbie traders huge price drops aren't always a bad thing when it's a good earnings report. Think of it as a cycle - Investors come in and some of them are investors who are adding the stock to their 401k, day traders, and swing traders. The day traders and swing traders will ride the wave up to as far as they think it's going to go or like this stock they will hold on to it until earnings and then when the earnings report comes out they wait for a little pop in the price and then they bail. certain stocks have more day traders and swing traders than others. I have a few of my favorites that I ride up every few weeks and then I bounce. This was nothing more than swing traders and long-term investors selling and even day traders jumping in and out of it a few times today. now comes the second part of the cycle where the new investors step in and we will hopefully ride it up, sell, and then give it to the new groups coming in. ...
OraSure Technologies Stock Forum
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Tuesday, 7th January at 7:05 am
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.
According to the most recent data available from t...
Still, it doesn't look ready quite yet.
OraSure Technologies Acquires Sherlock Biosciences
Thursday, 19th December at 4:02 pm
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
This acquisition expands OraS...
Take a look. See if you like it.
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
OraSure Technologies (NASDAQ: OSUR) has received a federal contract through the Rapid Response Partnership Vehicle (RRPV) to develop a Marburg Virus Disease (MVD) rapid antigen test. The initial contract is valued at $7.5 million over multiple years, with potential value up to $11 million. The funding from BARDA aims to achieve FDA 510(k) clearance for a single-use lateral f...
In reaction to earnings/guidance:
• $Coty Inc (COTY.US)$ +3.9%, $General Mills (GIS.US)$+2.6%
Other news:
• $Clene (CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C (CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income (AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune (ALPN.US)$ +2.3% (...
No comment yet